智通财经APP获悉，医药股全线重挫，截至发稿，康诺亚-B(02162)跌5.83%，报39.6港元；荣昌生物(09995)跌4.81%，报35.65港元；诺诚健华(09969)跌4.35%，报9.23港元；信达生物(01801)跌4.01%，报50.3港元。
消息面上，美国总统特朗普宣布，计划于周一签署重磅行政令，强制美国处方药支付与全球最低价国家相同的价格，预计处方药和药品价格几乎会立即下降30%至80%，全球药价将会上涨以达到平衡，多年来首次为美国带来公平。
长期以来，制药公司一直坚称，高药价是推动创新和研发新疗法的必要条件，改革这一体系将大幅削减收入并扼杀可能延长和改善生命的突破性疗法的研发。对此，特朗普反驳称，这意味着“美国‘冤大头’毫无理由地为这些高价买单”，他还预测，为了“平衡并首次为美国带来公平”，全球药价可能会上涨，这对国际医药市场可能产生深远影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.